239 related articles for article (PubMed ID: 27734956)
1. The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia.
Griebel G; Pichat P; Boulay D; Naimoli V; Potestio L; Featherstone R; Sahni S; Defex H; Desvignes C; Slowinski F; Vigé X; Bergis OE; Sher R; Kosley R; Kongsamut S; Black MD; Varty GB
Sci Rep; 2016 Oct; 6():35320. PubMed ID: 27734956
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
[TBL] [Abstract][Full Text] [Related]
3. LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment.
Li ML; Yang SS; Xing B; Ferguson BR; Gulchina Y; Li YC; Li F; Hu XQ; Gao WJ
Exp Neurol; 2015 Nov; 273():190-201. PubMed ID: 26341392
[TBL] [Abstract][Full Text] [Related]
4. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
[TBL] [Abstract][Full Text] [Related]
5. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
[TBL] [Abstract][Full Text] [Related]
6. GluN2C/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.
Suryavanshi PS; Ugale RR; Yilmazer-Hanke D; Stairs DJ; Dravid SM
Br J Pharmacol; 2014 Feb; 171(3):799-809. PubMed ID: 24236947
[TBL] [Abstract][Full Text] [Related]
7. Persisting cognitive deficits induced by low-dose, subchronic treatment with MK-801 in adolescent rats.
Li JT; Su YA; Guo CM; Feng Y; Yang Y; Huang RH; Si TM
Eur J Pharmacol; 2011 Feb; 652(1-3):65-72. PubMed ID: 21114996
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression.
Campo B; Kalinichev M; Lambeng N; El Yacoubi M; Royer-Urios I; Schneider M; Legrand C; Parron D; Girard F; Bessif A; Poli S; Vaugeois JM; Le Poul E; Celanire S
J Neurogenet; 2011 Dec; 25(4):152-66. PubMed ID: 22091727
[TBL] [Abstract][Full Text] [Related]
9. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
10. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Zhang C; Fang Y; Xu L
Schizophr Res; 2014 Nov; 159(2-3):376-84. PubMed ID: 25219486
[TBL] [Abstract][Full Text] [Related]
11. Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia.
Li ML; Gulchina Y; Monaco SA; Xing B; Ferguson BR; Li YC; Li F; Hu XQ; Gao WJ
Neurobiol Learn Mem; 2017 Apr; 140():52-61. PubMed ID: 28213064
[TBL] [Abstract][Full Text] [Related]
12. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
[TBL] [Abstract][Full Text] [Related]
13. Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia.
Matos M; Shen HY; Augusto E; Wang Y; Wei CJ; Wang YT; Agostinho P; Boison D; Cunha RA; Chen JF
Biol Psychiatry; 2015 Dec; 78(11):763-74. PubMed ID: 25869810
[TBL] [Abstract][Full Text] [Related]
14. Metformin reverses the schizophrenia-like behaviors induced by MK-801 in rats.
Wang X; Luo C; Mao XY; Li X; Yin JY; Zhang W; Zhou HH; Liu ZQ
Brain Res; 2019 Sep; 1719():30-39. PubMed ID: 31121159
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium nitroprusside in the acute dizocilpine (MK-801) animal model of schizophrenia.
Wang X; Ding S; Lu Y; Jiao Z; Zhang L; Zhang Y; Yang Y; Zhang Y; Li W; Lv L
Brain Res Bull; 2019 Apr; 147():140-147. PubMed ID: 30772438
[TBL] [Abstract][Full Text] [Related]
16. The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.
Shiraishi E; Suzuki K; Harada A; Suzuki N; Kimura H
J Pharmacol Exp Ther; 2016 Mar; 356(3):587-95. PubMed ID: 26675680
[TBL] [Abstract][Full Text] [Related]
17. The Novel, Nicotinic Alpha7 Receptor Partial Agonist, BMS-933043, Improves Cognition and Sensory Processing in Preclinical Models of Schizophrenia.
Bristow LJ; Easton AE; Li YW; Sivarao DV; Lidge R; Jones KM; Post-Munson D; Daly C; Lodge NJ; Gallagher L; Molski T; Pieschl R; Chen P; Hendricson A; Westphal R; Cook J; Iwuagwu C; Morgan D; Benitex Y; King D; Macor JE; Zaczek R; Olson R
PLoS One; 2016; 11(7):e0159996. PubMed ID: 27467081
[TBL] [Abstract][Full Text] [Related]
18. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
Brown JW; Rueter LE; Zhang M
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of TAK-071, a muscarinic M
Kurimoto E; Yamada R; Hirakawa T; Kimura H
Neurosci Lett; 2021 Nov; 764():136240. PubMed ID: 34509568
[TBL] [Abstract][Full Text] [Related]
20. The effects of psychotomimetic and putative cognitive-enhancing drugs on the performance of a n-back working memory task in rats.
Ko T; Evenden J
Psychopharmacology (Berl); 2009 Jan; 202(1-3):67-78. PubMed ID: 18825373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
